Voloridge Investment Management LLC Sells 67,376 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Voloridge Investment Management LLC decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 49.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 69,712 shares of the pharmaceutical company's stock after selling 67,376 shares during the period. Voloridge Investment Management LLC's holdings in Vertex Pharmaceuticals were worth $28,073,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Brown Lisle Cummings Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth about $30,000. Sugar Maple Asset Management LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $35,000. Golden State Wealth Management LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $37,000. Truvestments Capital LLC grew its stake in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after acquiring an additional 23 shares in the last quarter. Finally, Midwest Capital Advisors LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $41,000. Institutional investors own 90.96% of the company's stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This represents a 10.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ourania Tatsis sold 530 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares of the company's stock, valued at $27,825,928.26. The trade was a 0.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,813 shares of company stock valued at $1,889,514 in the last quarter. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Trading Up 0.5%

Shares of Vertex Pharmaceuticals stock traded up $1.97 during trading on Friday, reaching $436.00. The company's stock had a trading volume of 1,427,218 shares, compared to its average volume of 1,416,571. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a market cap of $111.96 billion, a price-to-earnings ratio of -198.18, a PEG ratio of 2.11 and a beta of 0.51. The firm's 50-day moving average is $476.26 and its two-hundred day moving average is $463.12. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Vertex Pharmaceuticals's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted $4.76 EPS. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of several recent analyst reports. BMO Capital Markets set a $545.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research note on Thursday, January 30th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and boosted their price objective for the company from $408.00 to $424.00 in a research note on Tuesday, February 11th. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $515.04.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.